This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Chemical and structural profiling of poly(ADP-ribose) polymerase (PARP) inhibitor selectivity	<p>Chemical and structural profiling of PARP inhibitors could help identify strategies for designing more selective inhibitors. <i>In vitro</i> studies determined the binding of 185 compounds, including clinical-stage PARP inhibitors, to purified catalytic domains from 13 of the 17 human PARPs. All of the clinical compounds and most of the other compounds bound to multiple PARPs. Next steps include developing selective inhibitors for several PARP family members.</p> <p>At least eight companies have PARP inhibitors in clinical trials for neurological indications or cancer.</p> <p>SciBX 5(9); doi:10.1038/scibx.2012.240 Published online March 1, 2012</p>	Unpatented; licensing status not applicable	<p>Wahlberg, E. <i>et al. Nat. Biotechnol.</i>; published online Feb. 19, 2012; doi:10.1038/nbt.2121</p> <p>Contact: Herwig Schöler, Karolinska Institute, Stockholm, Sweden e-mail: herwig.schuler@ki.se</p>